Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: Evidence for HLA-DM-independent processing

International Immunology

Volumn 9, Issue 10, 1997, Pages 1537-1543

  Khanna, Rajiv ^a   Burrows, Scott R ^a   Steigerwald Mullen, Patty M ^b   Moss, Denis J ^a   Kurilla, Michael G ^b   Cooper, Leanne ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Epstein Barr virus; Epstein Barr virus nuclear antigen 1; HLA DM; Immune recognition

Indexed keywords

ALANINE; CD4 ANTIGEN; CELL NUCLEUS ANTIGEN; GLYCINE; HLA D ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIRUS ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; VIRUS CELL TRANSFORMATION;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CELL LINE; EPITOPES; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-D ANTIGENS; HUMANS; IMMUNIZATION; IMMUNOLOGIC MEMORY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0030767401     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/9.10.1537     Document Type: Article

References (37)

1. Rowe, M., Rowe, D. T., Gregory, C. D., Young, L. S., Farrell, P. J., Rupani, H. and Rickinson, A. B. 1987. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 6:2743.
2. Rooney, C. M., Rowe, M., Wallace, L. E. and Rickinson, A. B. 1985. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature 317:629.
3. Trivedi, P., Masucci, M. G., Winberg, G. and Klein, G. 1991. The Epstein-Barr-virus-encoded membrane protein LMP but not the nuclear antigen EBNA-1 induces rejection of transfected murine mammary carcinoma cells. Int. J. Cancer 48:794.
4. Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald Mullen, P. M., Klein, G., Kurilla, M. G. and Masucci, M. G. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685.
5. Khanna, R., Burrows, S. R., Steigerwald Mullen, P. M., Thomson, S. A., Kurilla, M. G. and Moss, D. J. 1995. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology 214:633.
6. Zimber, U., Adldinger, H. K., Lenoir, G. M., Vuillaume, M., Knebel-Doeberitz, M. V., Laux, G., Desgranges, C., Wittmann, P., Freese, U., Schneider, U. and Bornkamm, G. W. 1986. Geographical prevalence of two types of Epstein-Barr virus. Virology 154:56.
7. Salter, R. D. and Cresswell, P. 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant T×B cell hybrid. EMBO J. 5:943.
8. Demotz, S. and Peleraux. A. 1996. Processing of DR1-restricted determinants from the fusion protein of measles virus following two distinct pathways. Mol. Immunol. 33:387.
9. Denzin, L. K., Robbins, N. F., Carboy Newcomb, C. and Cresswell, P. 1994. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity 1:595.
10. Wang, A., Lu, S. D. and Mark, D. F., 1984. Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. Science 224:1431.
11. Rosenberg, S. A., Grimm, E. A., McGrogan, M., Doyle, M., Kawasaki, E., Koths, K. and Mark, D. F. 1984. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 223:1412.
12. Hearing, J., Mulhaupt, Y. and Harper, S. 1992. Interaction of Epstein-Barr virus nuclear antigen 1 with the viral latent origin of replication. J. Virol. 66:694.
13. Frappier, L. and O'Donnell, M. 1991. Overproduction, purification, and characterization of EBNA1, the origin binding protein of Epstein-Barr virus. J. Biol. Chem. 266:7819.
14. Moss, D. J., Misko, I. S., Burrows, S. R., Burman, K., McCarthy, R. and Sculley, T. B. 1988. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 331:719.
15. Khanna, R., Burrows, S. R., Moss, D. J. and Silins, S. L. 1996. Peptide transporter (TAP-1/2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for CTL control of EBV-associated malignancies J. Virol. 70:5357.
16. k class II molecules in human APC containing deleted or mutated HLA DM genes. J. Immunol. 153:5382.
17. Denzin, L. K. and Cresswell, P. 1995. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 82:155.
18. Sherman, M. A., Weber, D. A. and Jensen, P. E. 1995. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 3:197.
19. Riberdy, J. M., Newcomb, J. R., Surman, M. J., Barbosa, J. A. and Cresswell, P. 1992. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 360:474.
20. Sette, A., Southwood, S., O'Sullivan, D., Gaeta, F. C., Sidney, J. and Grey, H. G. 1992. Effect of pH on MHC class II-peptide interactions, J. Immunol. 148:844.
21. Khanna, R., Burrows, S. R., Argaet, V. and Moss, D. J. 1994. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int. Immunol. 6:639.
22. Khanna, R., Burrows, S. R. and Moss, D. J. 1995. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59:387.
23. Burrows, S. R., Rodda, S. J., Suhrbier, A., Geysen, H. M. and Moss, D. J. 1992. The specificity of recognition of a cytotoxic T lymphocyte epitope. Eur. J. Immunol. 22:191.
24. Khanna, R., Jacob, C. A., Burrows, S. R. and Moss, D. J. 1993. Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection. J. Immunol. Methods 164:41.
25. Rowe, M., Khanna, R., Jacob, C. A., Argaet, V., Kelly, A., Powis, S., Belich, M., Croom Carter, D., Lee, S., Burrows, S. R., Moss, D. J. and Rickinson, A. B. 1995. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur. J. Immunol. 25:1374.
26. Khanna, R., Burrows, S. R., Kurilla, M. G., Jacob, C. A., Misko, I. S., Sculley, T. B., Kieff, E. and Moss, D. J. 1992. Localization of Epstein-Barr virus cytotoxic T-cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169.
27. Mellins, E., Smith, L., Arp, B., Cotner, T., Celis, E. and Pious, D. 1990. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 343:71.
28. Fling, S. P., Arp, B. and Pious, D. 1994. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 368:554.
29. Mellins, E., Kempin, S., Smith, L., Monji, T. and Pious, D. 1991. A gene required for class II-restricted antigen presentation maps to the major histocompatibility complex. J. Exp. Med. 174:1607.
30. Brooks, A., Hartley, S., Kjer-Nielsen, L., Perera, J., Goodnow, C. C. and Basten, A. 1991. Class II-restricted presentation of an endogenously derived immunodominant T-cell determinant of hen egg lysozyme. Proc. Natl Acad. Sci. USA 88:3290.
31. Pinet, V., Malnati, M. S. and Long, E. O. 1994. Two processing pathways for the MHC class II restricted presentation of exogenous influenza virus antigen. J. Immunol. 152:4852.
32. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer 58:69.
33. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl Acad. Sci. USA 91:9461.
34. + EBV-specific CTL. J. Immunol. 158:3619.
35. - T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161:1122.
36. Kern, D. E., Klarnet, J. P., Jensen, M. C. and Greenberg, P. D. 1986. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J. Immunol. 136:4303.
37. Ostrand Rosenberg, S., Roby, C. A. and Clements, V. K. 1991. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J. Immunol. 147:2419.